Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.00 – $0.20
3% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $31.8K | $0 | $0 | $0 | $3.1M | $13.9M | $1.7M |
| Cost of revenue | $19.9K | $0 | $25.0K | $19.8K | $24.7K | $1.3M | $4.2M | $578.6K |
| Gross profit | −$19.9K | $31.8K | −$25.0K | −$19.8K | −$24.7K | $1.8M | $9.7M | $1.1M |
| Gross margin | — | 100.0% | — | — | — | 57.2% | 69.6% | 65.9% |
| R&D | $6.0M | $10.1M | $1.9M | $3.8M | $4.1M | $2.0M | $1.7M | $1.6M |
| Operating income | −$7.3M | −$11.2M | −$2.9M | −$5.9M | −$6.9M | −$7.0M | $1.2M | −$9.0M |
| EBITDA | −$7.2M | −$11.1M | −$2.9M | −$5.8M | −$6.8M | −$6.8M | $1.4M | −$8.8M |
| Net income | −$5.9M | −$8.9M | −$2.4M | −$5.0M | −$5.8M | −$6.5M | $1.3M | −$9.1M |
| Net margin | — | -28067.5% | — | — | — | -210.0% | 9.3% | -534.6% |
| EPS (diluted) | -0.04 | -0.04 | -0.01 | -0.02 | -0.02 | -0.02 | 0.00 | -0.03 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $5M | $-0.01 | $-0.01–$-0.01 | 1 |
| 2027 | $6M | $-0.00 | $-0.00–$-0.00 | 1 |
Forward consensus · source: Financial Modeling Prep
FUTURA MEDICAL PLC ORD
No one on the platform currently holds FAMDF.
No tracked institution reports a position in FAMDF as of their last filing.
No one on the platform has traded FAMDF yet.
| $3M |
| — |
| KNBIFKane Biotech Inc. | $0.02 | +0.00% | $4M | — |
| MYNDFMYND Life Sciences Inc. | $0.01 | +0.00% | $657843 | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.6× sales vs its 24.3× historical median P/S.
Fair value ≈ $0.26 · price $0.01 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.